Genetic Disorders

Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Clinical Trial

Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Clinical Trial

Tonix Pharmaceuticals has received FDA clearance to begin Phase 2 trials for TNX-2900, a potential treatment for Prader-Willi syndrome, marking significant progress for a rare genetic disorder that causes life-threatening childhood obesity.

September 30, 2025
Telomir Pharmaceuticals Reports Preclinical Success for Telomir-1 in Progeria Cell Lines

Telomir Pharmaceuticals Reports Preclinical Success for Telomir-1 in Progeria Cell Lines

Telomir Pharmaceuticals' preclinical data shows Telomir-1's potential in preventing cellular aging in progeria cell lines, marking a significant advancement in treating Hutchinson-Gilford Progeria Syndrome (HGPS).

June 18, 2025